

Attorney Docket No.: 6133.224-US

U.S. Application No. 10/664,368

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Poulsen et al.

Confirmation No.: 4554

Application No.: 10/664,368

Group Art Unit: 3763

Filed: September 17, 2003

Examiner: Koharski, Christopher

For: Method and System for Assisting a User in Medical Self-Treatment, Said Self-Treatment Comprising a Plurality of Actions

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In accordance with Applicants' duty of disclosure under 37 C.F.R. § 1.56, and supplemental to the Information Disclosure Statement filed May 5, 2009, Applicants hereby submit the following Information Disclosure Statement under 37 C.F.R. §§ 1.97 and 1.98, and in conformance with MPEP 609 and 37 C.F.R. § 1.98(d).

Applicants hereby make of record the following commonly owned U.S. Application(s) which may not already be of record in the present application,

- U.S. App. No. 11/410,450 filed on April 25, 2006 by Liisberg (Attorney Docket No. 6644.204-US)

Applicant(s) may also submit herewith Office Action(s) and, *inter alia*, any documents cited therein, and these documents are listed on the accompanying Form(s) PTO-1449.

The Examiner is encouraged to review any associated Applicant responses in the above mentioned applications, and Applicant(s) assume(s) that due to the ease of review on PAIR by the Examiner, these responses need not be submitted/listed. Since prosecution

Attorney Docket No.: 6133.224-US

U.S. Application No. 10/664,368

may be ongoing in the herein mentioned application(s), Applicant(s) assume(s) that the Examiner will continue to evaluate the application(s) as needed.

The Examiner is requested to consider the attached Form PTO-1449, and to return the initialed and signed copy with the next communication from the U.S. Patent and Trademark Office.

Applicants hereby submit one Form PTO-1449 sheet for consideration by the Examiner in accordance with 37 C.F.R. §§ 1.56, 1.97, and 1.98:

Attorney Docket No.: 6133.224-US

U.S. Application No. 10/664,368

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application No.	<b>10/664,368</b>
				Filing Date	<b>September 17, 2003</b>
				Applicant	<b>Poulsen et al.</b>
				Art Unit	<b>3763</b>
				Examiner Name:	<b>Koharski, Christopher</b>
Sheet	<b>1</b>	of	<b>1</b>	Atty. Docket No.	<b>6133.224-US</b>

**U.S. PATENT DOCUMENTS**

EXAMINER INITIALS	Cite No.	DOCUMENT NUMBER Number –Kind Code <sup>(if known)</sup>	Issue/Publication Date MM-DD-YYYY	NAME of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		5,005,143	04-02-91	Altschuler	
		6,387,349	05-14-02	Moore	
		6,540,672	04-01-03	Simonsen et al.	
		6,602,469	08-05-03	Maus et al.	

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIALS	Cite No.	DOCUMENT NUMBER Number –Kind Code <sup>(if known)</sup>	Publication Date MM-DD-YYYY	NAME of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T
		WO 00/32258	06-08-00	Novo Nordisk A/S		
		WO 02/062212	08-15-02	Inverness Medical Ltd.		
		WO 03/023682	03-20-03	Univation Ltd.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T
		Non-Final Office Action dated September 17, 2009 in U.S. Appln. No. 11/410,450 filed April 25, 2006 by Liisberg	
		Final Office Action dated April 29, 2010 in U.S. Appln. No. 11/410,450 filed April 25, 2006 by Liisberg	

EXAMINER SIGNATURE	/Christopher Koharski/	DATE CONSIDERED	12/18/2010
--------------------	------------------------	--------------------	------------

Attorney Docket No.: 6133.224-US

U.S. Application No. 10/664,368

**REMARKS**

Pursuant to 37 C.F.R. § 1.98 copies of the U.S. patent documents (patents, application publications, and applications) are not being submitted herewith. Of course, should any of the documents not be readily available to the Examiner, the Examiner is requested to contact the undersigned and additional copies will be submitted.

Applicants note that Copyrighted material submitted with this Information Disclosure Statement may be delivered to the Government under license from the Copyright Clearance Center, Inc., or other rights holders – no further reproduction of such works is permitted.

Inclusion of any reference is not intended to constitute an admission that the reference is "prior art" unless it is specifically designated as such.

This information disclosure statement is being filed **after** the mailing date of any of a final action under 37 C.F.R. § 1.113, a notice of allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, but before, or simultaneously with, the payment of the issue fee.

Accompanying this information disclosure statement is the fee set forth in § 1.17(p) (currently \$180.00). The Examiner is hereby authorized to charge Deposit Account No. 14-1447 in the amount of \$180.00.

Applicants respectfully request that any references or other information listed above be made of record in this patent application. The Examiner is invited to call the undersigned if there are any questions concerning this submission or application.

Respectfully submitted,

Date: August 4, 2010

**/Marc A. Began, Reg. No. 48,829/**

Marc A. Began, Reg. No. 48,829  
for Wesley A. Nicolas  
Novo Nordisk Inc.  
Customer Number 23650  
(609) 987-5800